Cargando…

Autologous Hematopoietic Stem Cells Are a Preferred Source to Generate Dendritic Cells for Immunotherapy in Multiple Myeloma Patients

In multiple myeloma (MM), dendritic cells (DCs), and their precursors are prone to malignant cell-mediated regulation of function leading to low efficacy of DC vaccine. DCs taken directly from MM patient's body or derived from monocytes are fewer in numbers and are also dysfunctional. Here, we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shinde, Prajakta, Melinkeri, Sameer, Santra, Manas Kumar, Kale, Vaijayanti, Limaye, Lalita
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6536579/ https://www.ncbi.nlm.nih.gov/pubmed/31164886 http://dx.doi.org/10.3389/fimmu.2019.01079

Ejemplares similares

Compromised functionality of monocyte-derived dendritic cells in multiple myeloma patients may limit their use in cancer immunotherapy
por: Shinde, Prajakta, et al.
Publicado: (2018)

Transforming growth factor β1 accelerates and enhances in vitro red blood cell formation from hematopoietic stem cells by stimulating mitophagy
por: Kuhikar, Rutuja, et al.
Publicado: (2020)

Umbilical cord blood-derived CD11c(+) dendritic cells could serve as an alternative allogeneic source of dendritic cells for cancer immunotherapy
por: Kumar, Jeetendra, et al.
Publicado: (2015)

Exogenous Addition of Arachidonic Acid to the Culture Media Enhances the Functionality of Dendritic Cells for Their Possible Use in Cancer Immunotherapy
por: Kumar, Jeetendra, et al.
Publicado: (2014)

Nitric oxide has contrasting age-dependent effects on the functionality of murine hematopoietic stem cells
por: Jalnapurkar, Sapana, et al.
Publicado: (2016)

Differential ability of MSCs isolated from placenta and cord as feeders for supporting ex vivo expansion of umbilical cord blood derived CD34(+) cells
por: Kadekar, Darshana, et al.
Publicado: (2015)

Conditioned Medium from Placental Mesenchymal Stem Cells Reduces Oxidative Stress during the Cryopreservation of Ex Vivo Expanded Umbilical Cord Blood Cells
por: Kadekar, Darshana, et al.
Publicado: (2016)

Placenta-derived mesenchymal stem cells possess better immunoregulatory properties compared to their cord-derived counterparts–a paired sample study
por: Talwadekar, Manasi D., et al.
Publicado: (2015)

Expansion of Cord Blood CD34(+) Cells in Presence of zVADfmk and zLLYfmk Improved Their In Vitro Functionality and In Vivo Engraftment in NOD/SCID Mouse
por: M, Sangeetha V., et al.
Publicado: (2010)

Pharmacological Inhibition of Caspase and Calpain Proteases: A Novel Strategy to Enhance the Homing Responses of Cord Blood HSPCs during Expansion
por: V. M., Sangeetha, et al.
Publicado: (2012)

Physiological Cues Involved in the Regulation of Adhesion Mechanisms in Hematopoietic Stem Cell Fate Decision
por: Kulkarni, Rohan, et al.
Publicado: (2020)

Hypoxic Niche-Mediated Regeneration of Hematopoiesis in the Engraftment Window Is Dominantly Affected by Oxygen Tension in the Milieu
por: Moirangthem, Ranjita Devi, et al.
Publicado: (2015)

Data on the effect of oral feeding of Arachidonic acid or Docosahexanoic acid on haematopoiesis in mice
por: Limbkar, Kedar, et al.
Publicado: (2017)

Autologous Stem Cell Transplantation for Myeloma: Cytoreduction or an Immunotherapy?
por: Minnie, Simone A., et al.
Publicado: (2021)

Outcomes of Salvage Autologous Versus Allogeneic Hematopoietic Cell Transplantation for Relapsed Multiple Myeloma After Initial Autologous Hematopoietic Cell Transplantation
por: Wirk, Baldeep, et al.
Publicado: (2013)

Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma without Cryopreservation
por: Al-Anazi, Khalid Ahmed
Publicado: (2012)

Update on the Role of Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
por: Tosi, P., et al.
Publicado: (2012)

Mobilization Strategies in Myeloma Patients Intended for Autologous Hematopoietic Cell Transplantation
por: Jantunen, Esa, et al.
Publicado: (2023)

Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401
por: Chung, David J., et al.
Publicado: (2023)

Lenalidomide before and after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
por: Tuchman, S. A., et al.
Publicado: (2012)

Therapeutic effects of autologous hematopoietic stem cell transplantation in multiple myeloma patients
por: FU, CHENGCHENG, et al.
Publicado: (2013)

The Role of T Lymphocytes in Cancer Patients Undergoing Immunotherapy with Autologous Dendritic Cells
por: Rodrigues, Cláudia M., et al.
Publicado: (2011)

Cellular immunotherapy using dendritic cells against multiple myeloma
por: Nguyen-Pham, Thanh-Nhan, et al.
Publicado: (2012)

Sequential, Autologous Hematopoietic Stem Cell Transplant Followed by Renal Transplant in Multiple Myeloma
por: Bhowmik, D., et al.
Publicado: (2017)

Prevalence and Significance of Sarcopenia in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation
por: Williams, Alexis, et al.
Publicado: (2020)

Tandem Autologous Hematopoietic Stem Cell Transplantation in Very Young Patients with Multiple Myeloma
por: Naithani, Rahul, et al.
Publicado: (2020)

Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma
por: Kansagra, Ankit, et al.
Publicado: (2022)

Influence of Immunotherapy with Autologous Dendritic Cells on Innate and Adaptive Immune Response in Cancer
por: Matias, Bruna F., et al.
Publicado: (2013)

Immunotherapy Using Dendritic Cells against Multiple Myeloma: How to Improve?
por: Nguyen-Pham, Thanh-Nhan, et al.
Publicado: (2012)

Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation
por: Uy, Geoffrey L., et al.
Publicado: (2015)

Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma
por: Maffini, Enrico, et al.
Publicado: (2019)

Membranous Glomerulopathy After Autologous Hematopoietic Stem Cell Transplant in a Patient With Multiple Myeloma
por: Rodríguez Feria, Daniela, et al.
Publicado: (2021)

Trends in utilization of stored cryopreserved autologous peripheral hematopoietic cells intended for a second (or beyond) autologous hematopoietic cell transplantation in patients with multiple myeloma: a single center experience
por: Yassine, Farah, et al.
Publicado: (2023)

Immunotherapy of Malignant Melanoma with Tumor Lysate-Pulsed Autologous Monocyte-Derived Dendritic Cells
por: Kim, Dae Suk, et al.
Publicado: (2011)

Dendritic Cell-Based Immunotherapy in Multiple Myeloma: Challenges, Opportunities, and Future Directions
por: Verheye, Emma, et al.
Publicado: (2022)

Management of central nervous system involvement in multiple myeloma after autologous hematopoietic stem cell transplantation
por: Mousavi-Fatemi, Khatereh, et al.
Publicado: (2020)

Effect of autologous hematopoietic stem cell transplant on the development of second primary malignancies in multiple myeloma patients
por: Rosenberg, A. S., et al.
Publicado: (2021)

Outcomes of Non-Cryopreserved Versus Cryopreserved Peripheral Blood Stem Cells for Autologous Stem Cell Transplantation in Multiple Myeloma
por: Piriyakhuntorn, Pokpong, et al.
Publicado: (2020)

Dendritic Cell-Based Cancer Immunotherapy against Multiple Myeloma: From Bench to Clinic
por: Hoang, My-Dung, et al.
Publicado: (2015)

Bendamustine, etoposide and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in patients with multiple myeloma
por: Green, Damian J., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_nvc1l3dcafjn30nakhnjg5fr76